OMass Therapeutics appoints Jonathan Montagu as Non-Executive Director


June 12, 2019

OMass Therapeutics appoints Jonathan Montagu as Non-Executive Director

Oxford, 12 June 2019 – OMass Therapeutics (“OMass”), a drug discovery company using structural mass spectrometry to discover novel medicines, today announced the appointment of Jonathan Montagu as a Non-Executive Director. Jonathan brings more than 20 years of leadership experience in both biotechnology and high-technology industries.

“We are delighted to welcome Jonathan to our Board of Directors,” said Dr Edward Hodgkin, Chairman, OMass Therapeutics and Partner at Syncona Investment Management Limited. “Jonathan is a highly accomplished leader in our industry with extensive experience in building chemistry platform companies. We look forward to drawing on his expertise as we develop a pipeline of differentiated therapeutics that leverage OMass’ unique ability to interrogate the biology of intact protein complexes using mass spectrometry.”

Jonathan Montagu, commented:
“I am delighted to join the Board of Directors of OMass at an exciting time in the company’s development. Native mass spectrometry can be used to generate a high resolution, biophysical map of protein structure and interactions and I look forward to helping the Company to leverage this capability to bring transformative therapies to the clinic and make a difference in the lives of patients.”

Jonathan is the Co-Founder and Chief Executive Officer of HotSpot Therapeutics, a company targeting nature’s regulatory mechanisms to create high precision allosteric medicines for the treatment of serious autoimmune and metabolic diseases. Prior to co-founding HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics, where he helped establish the company’s drug discovery platform and pipeline. He also served as Vice President, Business Development at Concert Pharmaceuticals, and was instrumental in securing a $1B multi-product transaction for the company with GSK.

Jonathan trained as a chemist at Oxford University, Cold Spring Harbor Laboratory, The Scripps Research Institute, and Cancer Research UK.

OMass Therapeutics was formed in 2016 as a spin-out from the University of Oxford and completed a £14 million Series A financing in 2018 from Syncona and Oxford Sciences Innovation. OMass applies structural mass spectrometry technology developed in the laboratory of Prof. Dame Carol Robinson to the discovery of novel therapeutics against complex protein targets, including membrane proteins.

– Ends –

Further information:
JW Communications
Julia Wilson +44 (0)7818 430877

Notes for Editors:

About OMass Therapeutics
OMass Therapeutics is a private pharmaceutical company, focused on structural mass spectrometry to discover novel medicines. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulating complex formation. These methods are being applied to drug discovery for a variety of complex targets, including membrane proteins, addressing severe unmet medical needs. OMass is backed by Syncona Ltd and Oxford Sciences Innovation. For further information please visit the Company’s website at:

MORERelated News
OMass Therapeutics Expands Leadership Team with Two New Appointments
Appointment of two senior executives in newly created roles Peter Phillips M.D., Ph.D. joins as Senior Vice President of Clinical...
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
Jim Geraghty joins as Independent Director and Chair, bringing US and international experience from Genzyme and as NED and chair...
OMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio Progress
Move to new purpose-built 16,000ft2 flagship site on ARC Oxford campus to support continued company growth Expansion of senior leadership...